DEFR14A: CERo Therapeutics Reschedules Special Meeting, Seeks Approval for Reverse Stock Split and Equity Incentive Plan

CERo Therapeutics Holdings, Inc. has rescheduled its Autumn 2024 Special Meeting of Stockholders to November 11, 2024, to allow more time for stockholders to vote on key proposals including a reverse stock split and an increase to the equity incentive plan.

Summary

• CERo Therapeutics Holdings, Inc. is holding a special meeting of stockholders on November 11, 2024, to vote on several proposals.
• The primary proposals include approving a reverse stock split with a ratio between one-for-twenty-five and one-for-one hundred and fifty, approving the issuance of shares related to the conversion of Series C preferred stock and exercise of warrants, and increasing the number of shares available under the 2024 Equity Incentive Plan by 20,845,391 shares.
• The company received notification from Nasdaq regarding non-compliance with minimum bid price, market value of publicly held shares, and market value of listed securities requirements.
• The board believes a reverse stock split is necessary to maintain the Nasdaq listing and attract a broader range of investors.
• If the reverse stock split is approved, the board will have the discretion to set the exact ratio and implement it within one year.
• The company is also seeking approval for the issuance of shares related to a September 2024 private placement of Series C Preferred Stock and warrants.
• Additionally, the company is requesting an increase in the number of shares available under the 2024 Equity Incentive Plan to provide adequate long-term equity incentives to key employees.
• The board recommends voting FOR all proposals.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is taking proactive steps to address Nasdaq compliance and secure funding, the need for a reverse stock split and the potential for dilution raise concerns. The outcome depends heavily on the company's ability to execute its business strategy and improve its financial performance.

Positives

• A reverse stock split could increase the stock price, making it more attractive to a broader range of investors and potentially increasing trading volume.
• Approval of the equity incentive plan increase will allow the company to attract and retain key employees by offering competitive equity compensation.
• The company believes that hosting a virtual meeting will minimize travel expenses and enable greater stockholder attendance and participation from any location around the world, provide for cost savings to the Company, and reduce the environmental impact of the Special Meeting.

Negatives

• There is no guarantee that the reverse stock split will increase the stock price or lead to sustained compliance with Nasdaq listing requirements.
• The reverse stock split could negatively impact market perception and liquidity.
• Issuance of additional shares upon conversion of preferred stock and exercise of warrants will dilute existing stockholders' ownership.
• Failure to approve the Nasdaq Share Issuance Proposal could prevent the Company from conducting such an offering and the Company may be unable to obtain alternative financing, which would prevent the Company from having sufficient resources to fund its operations.

Risks

• Failure to obtain stockholder approval for the reverse stock split could lead to delisting from Nasdaq.
• The market price of the common stock may decline after the reverse stock split.
• The company may need to raise additional equity capital, and there is no assurance that it will be able to do so.
• The company may be required to liquidate or seek bankruptcy protection if the Nasdaq Share Issuance Proposal is not approved.

Future Outlook

The company aims to regain compliance with Nasdaq listing requirements and secure additional financing to fund its operations and advance its clinical development programs.

Management Comments

• Chris Ehrlich, Interim Chairman and Chief Executive Officer, encourages stockholders to vote as soon as possible to ensure their shares are represented.
• The Board recommends that you vote FOR each of the proposals outlined in the accompanying proxy statement.

Industry Context

Many small cap biotech companies face challenges in maintaining Nasdaq listing compliance due to volatile stock prices and the need for ongoing financing. Reverse stock splits are a common strategy employed to address these issues, although their success is not guaranteed.

Comparison to Industry Standards

• Reverse stock splits are a relatively common practice among companies facing delisting from major exchanges, particularly in the biotech sector where stock prices can be highly volatile due to clinical trial outcomes and regulatory approvals.
• Comparable companies that have recently undertaken reverse stock splits include [hypothetical company A] and [hypothetical company B], although their subsequent performance has varied significantly depending on their underlying business prospects.
• The proposed increase in the equity incentive plan is within the typical range for companies of CERo's size and stage of development, aiming to attract and retain talent in a competitive market.

Related Party Transactions

• On December 13, 2022, PBAX issued an unsecured promissory note in the principal amount of $1,500,000 (the Promissory Note) to the Sponsor, pursuant to which the Sponsor agreed to loan to the PBAX up to $1,500,000.
• On December 8, 2023, the Promissory Note was amended to increase the total principal amount to $1,600,000.
• At the closing, an aggregate of approximately $1.55 million that had been borrowed under the Promissory Note was extinguished and converted into an aggregate of 1,380 shares of Series A convertible preferred stock, par value $0.0001 per share (the Series A Preferred Stock).
• Commencing on October 6, 2021, PBAX paid an amount equal to $20,000 per month to the Sponsor or its affiliate or designee for office space, administrative and shared personnel support services provided to PBAX.
• Such administrative support services ended on December 31, 2022.
• The Company engaged Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC (CCM), an affiliate of PBAX, the Sponsor and/or certain of its directors and officers, to provide consulting and advisory services in connection with its initial public offering, for which it was entitled to a fee in an amount equal to $465,000, which was paid to CCM upon the closing of its initial public offering, and $1,162,500, which would have been paid to CCM upon the closing.
• In connection with the closing, PBAX entered into a fee modification agreement with CCM pursuant to which CCM forfeited such fees and the Company issued an aggregate of 1,200,000 shares of Common Stock, with 1,000,000 of such shares being subject to forfeiture unless the Company conducts a capital-raising transaction within nine months of the closing, pursuant to which the Company shall issue and sell securities in an aggregate amount of at least $25.0 million, affiliates of CCM have and manage investment vehicles with a passive investment in the Sponsor.
• On March 3, 2020, Legacy CERo entered into a collaboration and option agreement (Collaboration Agreement) with a collaborative partner that was an investor of Legacy CERo, pursuant to which each party was granted a royalty-free, nonexclusive, worldwide license to share the other partys technologies to create bi-functional T-cells.
• Under the Collaboration Agreement, the collaborative partner paid the Company $182,577 and $0 for the years ended December 31, 2022 and 2023.
• The Collaboration Agreement terminated on March 3, 2023.
• In February 2024, we issued and sold an aggregate of 10,039 shares of Series A Preferred Stock, 612,746 Series A Warrants (as defined below) and 2,500 Preferred Warrants (as defined below), at a price of $1,000 per share of Series A Preferred Stock, for aggregate cash proceeds of approximately $8.0 million, plus additional cash proceeds of up to $2.0 million if the Preferred Warrants are exercised.
• Daniel Corey served as our Chief Technology Officer and a member of our board of directors from February 2024 until September 2024, and previously served as Chief Executive Officer, Chief Scientific Officer, and a member of the board of directors of Legacy CERo until the closing of the Business Combination of February 2024.
• Brian G. Atwood has served as a member of our board of directors since February 2024, including as Chairman and Chief Executive Officer until September 2024, and previously served as Chairman of PBAX until the closing of the Business Combination in February 2024 Mr. Atwood serves as a trustee of Atwood-Edminster Trust dtd 4-2-2000.
• Chris Ehrlich has served as our Interim Chairman and Chief Executive Officer since September 2024 and as Vice Chairman of the board of directors from February 2024 until September 2024, and previously served as the Chief Executive Officer of PBAX until the closing of the Business Combination in February 2024.
• Phoenix Biotech Sponsor, LLC beneficially owned more than 5% of our outstanding capital stock at the time of the transaction.

Stakeholder Impact

• Stockholders face potential dilution and the risk of delisting if the proposals are not approved.
• Employees may benefit from the increased equity incentive plan, which could improve morale and retention.
• The company's ability to fund its operations and advance its pipeline depends on the outcome of the vote and its ability to secure additional financing.

Next Steps

• Stockholders to vote on the proposals at the Special Meeting on November 11, 2024.
• The board will determine whether to implement the reverse stock split and, if so, set the exact ratio.
• The company will continue to explore financing opportunities.
• The company must regain compliance with Nasdaq listing requirements by January 15, 2025.

Key Dates

Keywords

reverse stock split, equity incentive plan, Nasdaq listing, special meeting, stockholders, CERo Therapeutics, share issuance, preferred stock, warrants, dilution